Why the study?
Are all P2Y12-inhibitors equal for monotherapy after coronary stenting?
Are all P2Y12-inhibitors equal for monotherapy after coronary stenting?
This expert review discusses the comparative efficacy and future directions of P2Y12-inhibitor monotherapy (clopidogrel, prasugrel, or ticagrelor) after percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
No P2Y12 inhibitor shows clear superiority for post-PCI monotherapy; leaves open need for dedicated RCTs.
INTRODUCTION: -inhibitor monotherapy. AREAS COVERED: -inhibitor monotherapy after PCI using either clopidogrel, prasugrel, or ticagrelor. Furthermore, we discuss ongoing trials and future directions for research. EXPERT OPINION: -inhibitor monotherapy and what the optimal antithrombotic therapy beyond 12 months is.
No takes yet. Share an insight, caveat, or question.
Sangen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: